EANM Young Authors’ Award

[⁶⁸Ga]FAPI-46PET/CT for preoperative assessment of peritoneal carcinomatosis- Preliminary analysis of FAPeCa trial
Arçay Öztürk¹, G. Liberale², A. Hendlisz³, L. Polastro³, A. Veron Sanchez⁴, A. Deleu¹, P. Kristanto⁵, Z. Wimana⁶, S. Vercauteren⁶, P. Flamen¹;
¹Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Department of Nuclear Medicine, Brussels, BELGIUM, ²Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB),Department of Surgery, Brussels, BELGIUM, ³Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB),Department of Medical Oncology, Brussels, BELGIUM, ⁴Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB),Department of Radiology, Brussels, BELGIUM, ⁵Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Data Center, Brussels, BELGIUM, ⁶Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Department of Radiopharmacy, Brussels, BELGIUM.

PSMA-PET and PROMISE re-define stage and risk in prostate cancer patients
Karpinski^1,2, J. Hüsing², K. Claassen^2,3, L. Möller², H. Kajüter², F. Oesterling², V. Grünwald^4,5, L. Umutlu⁶, H. Lanzafame¹, T. Telli¹, A. Merkel-Jens⁷, A. Hüsing⁷, C. Kesch⁸, K. Herrmann¹, A. Stang^2,7, B. Hadaschik⁸, W. P. Fendler¹;
¹Department of Nuclear Medicine, DKTK and NCT University Hospital Essen, Essen, GERMANY, ²Cancer Registry NRW, Bochum, GERMANY, ³Department of Medical Statistics and Epidemiology, Medical School Hamburg, Hamburg, GERMANY, ⁴Department of Urology, Pediatric Urology and Urooncology University Hospital Essen, Essen, GERMANY, ⁵Department for Medical Oncology, University Hospital Essen, Essen, GERMANY, ⁶Department of Radiology University Hospital Essen, Essen, GERMANY, ⁷Institute of Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Essen, GERMANY, ⁸Department of Urology, Pediatric Urology and Urooncology University Hospital Essen, Essen, Germany, Essen, GERMANY.

Early Outcomes of ²²⁵Ac-DOTA-LM3 Radiopeptide Therapy for Resistant Neuroendocrine Tumors: An Assessment Using Theranostic Response Criteria In Solid Tumors (THERCIST)
Eismant¹, L. Greifenstein¹, E. Perrone², R. P. Baum¹;
¹CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, GERMANY, ²Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Rome, ITALY.

© Faistauer Photography

Lutetium-177-PSMA-617 in oligo-metastatic hormone sensitive prostate cancer (Bullseye)
B. Privé1, C. H. J. Muselaers1, D. Meijer2, W. A. Van Gemert1, B. Timmermans1, M. J. R. Janssen1, M. A. Jonker1, M. de Groot1,
I. M. van Oort1, N. Mehra1, W. R. Gerritsen1, E. Alevroudis3, A. Vrachimis3, J. A. Gietema4, M. Gotthardt1, A. N. Vis2, I. J. de Jong4,
A. J. Witjes1, W. Noordzij4, D. E. Oprea-Lager2, J. Nagarajah1;
1Radboudumc, Nijmegen, NETHERLANDS, 2Amsterdam University Medical Centers, Amsterdam, NETHERLANDS,
3German Oncology Center, Limassol, CYPRUS, 4University Medical Center Groningen, Groningen, NETHERLANDS.

RadioFACS reveals [18F]FDG uptake in a KRAS induced lung cancer model is driven by immune cells but not tumor cell metabolism
C. Vraka1, M. Homolya2, T. Patsch1, A. Spittler3, E. Casanova2, S. Grünert1, M. Hacker1, C. Philippe1;
1Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA,
2Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, AUSTRIA,
3Core Facility Flow Cytometry and Department of Surgery, Research Laboratories, Medical University of Vienna, Vienna, AUSTRIA

Molecular imaging predicts response absence to T-DM1 in advanced HER2-positive breast cancer: final results from a prospective phase II ZEPHIR trial
Mileva¹, E. G. de Vries², T. Guiot³, Z. Wimana⁴, A. Deleu¹, C. Schröder^5,6, Y. Lefebvre¹, M. Paesmans⁷, S. Stroobants⁸, M. Huizing⁹, P. Aftimos¹⁰, J. Tol¹¹, W. Van der Graaf¹², W. Oyen^13,14,15, D. Vugts¹⁶, C. Menke-van der Houven van Oordt¹², A. Brouwers¹⁷, M. Piccart-Gebhart¹⁰, P. Flamen¹, G. Gebhart¹;
¹Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, ²Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, Groningen, NETHERLANDS, ³Department of Medical Physics, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, ⁴Department of Radiopharmacy, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, ⁵Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, ⁶Department of Medical Oncology, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, NETHERLANDS, ⁷Data center, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, ⁸Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Antwerp, BELGIUM, ⁹Department of Medical Oncology, Antwerp University Hospital, Edegem, Antwerp, BELGIUM, ¹⁰Department of Medical Oncology, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, ¹¹Department of Internal Medicine, Jeroen Bosch Ziekenhuis, Den Bosch, the Netherlands, Den Bosch, NETHERLANDS, ¹²Department of Medical Oncology, Amsterdam UMC location VUMC, Cancer Centre Amsterdam, Amsterdam, NETHERLANDS, ¹³Humanitas Clinical and Research Center, Humanitas University, Milan, ITALY, ¹⁴Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, NETHERLANDS, ¹⁵Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, NETHERLANDS, ¹⁶Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Cancer Center Amsterdam, Amsterdam, NETHERLANDS, ¹⁷Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS.

PSMA and FDG PET as Predictive and Prognostic Biomarkers in Men with Metastatic, Castration-Resistant Prostate Cancer (mCRPC): an Analysis of the Randomised, Phase 2 Trial of [177Lu]Lu-PSMA-617 Versus Cabazitaxel (TheraP, ANZUP 1603)
J. Buteau¹, A. Martin², L. Emmett³, A. Iravani⁴, S. Sandhu¹, A. M. Joshua³, R. J. Francis⁵, A. Y. Zhang², A. M. Scott⁶, S. Lee⁶, A. Azad¹, M. McJannett⁷, M. R. Stockler⁸, S. Williams¹, I. D. Davis⁹, M. S. Hofman¹;
¹Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, ²NHMRC Clinical Trials Centre, Sydney, AUSTRALIA, ³St-Vincent’s Hospital, Sydney, AUSTRALIA, ⁴Washington University, St. Louis, MO, UNITED STATES OF AMERICA, ⁵Sir Charles Gairdner Hospital, Perth, AUSTRALIA, ⁶Austin Health, Melbourne, AUSTRALIA, ⁷ANZUP, Sydney, AUSTRALIA, ⁸NHMRC CTC, Sydney, AUSTRALIA, ⁹Monash University and Eastern Health, Melbourne, AUSTRALIA.

Next generation PET/CT imaging in meningioma using the novel SSTR-targeting peptide 18F-SiTATE – first clinical experiences
M. Unterrainer¹, S. C. Kunte¹, L. M. Unterrainer¹, A. Delker¹, S. Lindner¹, M. Brendel1, A. Holzgreve1, W. G. Kunz1, C. C. Cyran1, J. Ricke1, K. Jurkschat2, C. Waengler3, B. Waengler3, R. Schirrmacher4, M. Niyazi1, J. Tonn¹, L. Beyer¹, P. Bartenstein¹, N. L. Albert¹;
¹University of Munich, Munich, GERMANY, ²TU Dortmund, Dortmund, GERMANY, ³University of Heidelberg, Heidelberg, GERMANY, ⁴University of Alberta, Edmonton, AB, CANADA.

[¹⁸F]AlF-NOTA-octreotide vs. [⁶⁸Ga]Ga-DOTA-somatostatin analogue PET in neuroendocrine tumour patients: final results of a prospective multicentre trial
E. Pauwels¹, F. Cleeren², T. Tshibangu², M. Koole¹, K. Serdons¹, L. Boeckxstaens¹, J. Dekervel³, T. Vandamme^4,5, W. Lybaert⁵, B. Van den Broeck⁶, P. M. Clement⁷, K. Geboes⁸, E. Van Cutsem³, S. Stroobants⁹, C. Verslype³, G. Bormans², C. M. Deroose¹;
¹Nuclear Medicine, University Hospitals Leuven; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM, ²Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, BELGIUM, ³Digestive Oncology, University Hospitals Leuven, Leuven, BELGIUM, ⁴Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, BELGIUM, ⁵Oncology, NETwerk Antwerpen-Waasland CoE, Antwerpen, BELGIUM, ⁶Nuclear Medicine, Ghent University Hospital, Ghent, BELGIUM, ⁷General Medical Oncology, University Hospitals Leuven, Leuven, BELGIUM, ⁸Digestive Oncology, Department of Gastroenterology, Ghent University Hospital, Ghent, BELGIUM, ⁹Nuclear Medicine, Antwerp University Hospital; Molecular Imaging and radiology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, BELGIUM.

Longitudinal Evaluation Of The First Mutant Huntingtin PET Radioligand As A Marker For mHTT Lowering Therapies For Huntington’s Disease
D. Bertoglio¹, J. Verhaeghe¹, S. De Lombaerde^1,2, F. Zajicek1, T. Vasilkovska¹, A. Miranda³, A. Gaertner⁴, B. Huscher⁴, A. Kakoulidou⁴, I. Cardaun⁴, A. Cornelius⁴, T. Schwagarus⁴, A. Van der Linden¹, S. Stroobants^1,2, Y. Wang5, M. Skinbjerg⁵, C. Dominguez⁵, V. Khetarpal⁵, L. Liu⁵, I. Munoz-Sanjuan⁵, J. Bard⁵, S. Staelens¹;
¹University of Antwerp, Wilrijk, BELGIUM, ²Antwerp University Hospital, Edegem, BELGIUM, ³University of Antwerp, Antwerpen, BELGIUM, ⁴Evotec SE, Hamburg, GERMANY, ⁵CHDI Management/CHDI Foundation, Los Angeles, CA, UNITED STATES OF AMERICA.

A pilot study comparing 18F-FDG PET/CT and 68Ga-FAPI PET/CT for initial staging of early operable and locally advanced breast cancers
P. Chandra, K. Senthil, M. Sridev, G. Chandran, J. Kumar, M. Merlin, P. Priya, J. Sangeetha, S. Nath;
MIOT international, Chennai, INDIA.

⁶⁸Ga-FAPI-04 PET/CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-related interstitial lung disease
C. Schmidkonz¹, J. Distler², C. Treutlein³, A. Atzinger¹, O. Prante¹, P. Ritt¹, T. Götz¹, T. Bäuerle¹, M. Cordes¹, M. Köhner¹, T. Kuwert¹, A. Ramming², G. Schett², C. Bergmann²;
¹University Hospital Erlangen, Department of Nuclear Medicine, Erlangen, GERMANY, ²University Hospital Erlangen, Department of Rheumatology, Erlangen, GERMANY, ³University Hospital Erlangen, Department of Radiology, Erlangen, GERMANY.

Ratiometric relationship between γH2AX imaging and Lutetium-177 is predictive of survival following radionuclide therapy in vivo
E. O’Neill, G. M. Dias, B. Cornelissen;
University of Oxford, Oxford, UNITED KINGDOM.

[¹⁸F]AlF-NOTA-octreotide PET imaging: Pharmacokinetics, biodistribution, and head-to-head comparison with [⁶⁸Ga]Ga-DOTATATE in neuroendocrine tumour patients
E. Pauwels¹, F. Cleeren², T. Tshibangu², M. Koole¹, K. Serdons¹, J. Dekervel³, E. Van Cutsem³, C. Verslype³, K. Van Laere¹, G. Bormans², C. M. Deroose¹;
¹Nuclear Medicine, University Hospitals Leuven; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM, ²Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, BELGIUM, ³Digestive Oncology, University Hospitals Leuven, Leuven, BELGIUM.

[¹⁷⁷Lu]Lu-PSMA-617 in low-volume metastatic hormone sensitive prostate cancer: a prospective pilot study
B. Prive¹, S. M. B. Peters¹, C. H. J. Muselaers¹, P. Zamecnik¹, M. J. R. Janssen¹, T. W. J. Scheenen¹, M. W. Konijnenberg¹, J. Verzijlbergen¹, W. R. Gerritsen¹, N. Mehra¹, D. M. Somford², J. A. Van Basten², I. M. Van Oort¹, J. Sedelaar¹, J. O. Barentsz¹, S. Heskamp¹, M. Gotthardt¹, J. Witjes¹, J. Nagarajah¹;
¹Radboudumc, Nijmegen, NETHERLANDS, ²Canisius Wilhelmina Hospital, Nijmegen, NETHERLANDS.

Fluorine-18 Labeled FAPI-Tracers For PET Imaging
T. Lindner¹, A. Altmann^1,2, F. L. Giesel¹, C. Kratochwil¹, C. Kleist¹, S. Kraemer¹, J. Debus^3,4, W. Mier¹, U. Haberkorn^1,2,5;
¹Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GERMANY, ²Clinical Cooperation Unit Nuclear Medicine, German Cancer research Center (DKFZ), Heidelberg, GERMANY, ³Dept. of Radiation Oncology, University Hospital Heidelberg, Heidelberg, GERMANY, ⁴Clinical Cooperation Unit Radiation Oncology, German Cancer research Center (DKFZ), Heidelberg, GERMANY, ⁵Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, GERMANY.

First Results of Targeted Alpha Peptide Receptor Radionuclide Therapy Using Ac-225 DOTATOC for Progressive Metastatic Neuroendocrine Neoplasms
H. R. Kulkarni, J. Zhang, A. Singh, C. Schuchardt, R. P. Baum;
THERANOSTICS Center for Molecular Radiotherapy and Precision Oncology, Zentralklinik Bad Berka, Bad Berka, GERMANY.

Tandem PSMA Radioligand Therapy Using Ac-225 and Lu-177 in Advanced Prostate Cancer: Safety and Efficacy
H. R. Kulkarni, J. Zhang, A. Singh, A. Mishra, C. Schuchardt, R. P. Baum;
THERANOSTICS Center for Molecular Radiotherapy and Precision Oncology, Zentralklinik Bad Berka, Bad Berka, GERMANY.

Imaging DNA Damage in vivo following [1⁷⁷Lu]Lu-DOTATATE therapy in a model of pancreatic neuroendocrine cancer
E. O’Neill¹, V. Kersemans¹, P. Allen¹, S. Terry², J. Baguña Torres¹, S. Smart¹, B. Quan Lee¹, N. Falzone¹, K. Vallis¹, M. Konijnenberg³, M. de Jong³, J. Nonnekens³, B. Cornelissen¹;
¹University of Oxford, Oxford, UNITED KINGDOM, ²King’s College London, London, UNITED KINGDOM, ³Erasmus MC, Rotterdam, NETHERLANDS.

First extensive preclinical evaluation of PSMA-specific tracers for prostate cancer radioligand therapy
E. Ruigrok, S. U. Dalm, E. de Blois, N. van Vliet, D. C. van Gent, J. Haeck, C. de Ridder, D. Stuurman, M. W. Konijnenberg, W. M. van Weerden, M. de Jong, J. Nonnekens;
Erasmus MC, Rotterdam, NETHERLANDS.

Clinical outcome of 121 patients after PSMA-targeted radioguided surgery for early biochemical recurrent prostate cancer
M. Kroenke¹, T. Horn², I. Rauscher¹, S. Robu³, M. Schottelius³, H. Wester³, T. Maurer², W. Weber¹, M. Eiber¹;
¹Department of Nuclear medicine, Klinikum rechts der Isar, TUM, Munich, GERMANY, ²Department of Urology, Klinikum rechts der Isar, TUM, Munich, GERMANY, ³Chair of Pharmaceutical Radiochemistry, Department of Chemistry, TUM, Munich, GERMANY.

A Complete Response following A Single Treatment with 225Ac-RPS-074 in LNCaP Xenografts
J. M. Kelly¹, A. Amor-Coarasa¹, S. Ponnala¹, N. A. Thiele², A. Nikolopoulou¹, C. Williams Jr.¹, J. Urgiles¹, J. J. Wilson², J. W. Babich¹;
¹Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA, ²Cornell University, Ithaca, NY, UNITED STATES OF AMERICA.

First evidence for a dose-response relationship in hepatic holmium-166 radioembolization
R. Bastiaannet, C. van Roekel, M. L. J. Smits, R. C. G. Bruijnen, J. F. Prince, H. W. A. M. de Jong, M. G. E. H. Lam; ;
University Medical Center Utrecht, Utrecht, NETHERLANDS.

Development Of Stroma-targeted Theranostics Based On Inhibitors Of Fibroblast Activating Protein
T. Lindner, A. Loktev, A. Altmann, F. Giesel, C. Kratochwil, W. Mier, U. Haberkorn;
University Hospital Heidelberg, Heidelberg, GERMANY.

Novel targeted radionuclide therapy approach enhances response to immune checkpoint blockade in murine melanoma
R. Hernandez, R. Patel, J. Grudzinski, E. Aluicio-Sarduy, R. Brown, R. Sriramaneni, J. W. Engle, P. M. Sondel, Z. S. Morris, J. P. Weichert;
University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA.

Dual-labeled PSMA-11 for PET/CT imaging and precise fluorescence guided intraoperative identification of prostate cancer
A. Baranski¹, M. Schäfer¹, U. Bauder-Wüst¹, M. Roscher¹, J. Schmidt¹, E. Stenau¹, T. Simpfendörfer², L. Maier-Hein¹, B. Hadaschik³, U. Haberkorn², K. Kopka¹, M. Eder^4,1,5;
¹German Cancer Research Center, Heidelberg, GERMANY, ²University Hospital, Heidelberg, GERMANY, ³University Hospital, Essen, GERMANY, ⁴University Hospital, Freiburg, GERMANY, ⁵German Cancer Consortium, Heidelberg, GERMANY.

First experience using LMI1195 in patients with the suspicion of pheochromocytoma or paraganglioma
C. Rischpler¹, A. M. Schlitter¹, M. Herz¹, B. Yousefi¹, A. von Werder¹, R. Tauber¹, T. Maurer¹, K. Scheidhauer¹, S. Robinson², C. Orlandi², S. G. Nekolla¹, M. Schwaiger¹;
¹Technical University Munich, Munich, GERMANY, ²Lantheus Medical Imaging, N. Billerica, MA, UNITED STATES OF AMERICA.

TSPO-PET for high-grade glioma imaging using the novel ligand [18F]GE-180 – first in human results in the course of radiotherapy
M. Unterrainer¹, D. Fleischmann¹, S. Lindner¹, A. Brunegraf¹, F. Vettermann¹, L. Vomacka¹, M. Brendel¹, R. Rupprecht², C. Belka¹, P. Bartenstein¹, M. Niyazi¹, N. Albert¹;
¹Ludwig-Maximilian-University Munich, München, GERMANY, ²University of Regensburg, München, GERMANY.

Monitoring tumor PD-L1 expression with microSPECT/CT during radiotherapy
S. Heskamp, J. D. M. Molkenboer-Kuenen, G. W. Sandker, P. J. Wierstra, J. Bussink, O. C. Boerman;
Radboud University Nijmegen Medical Centre, NIJMEGEN, NETHERLANDS.

Radiocobalt-labeled anti-HER1 affibody molecule DOTA-ZEGFR:2377 for imaging of low HER1 expression in prostate cancer pre-clinical model
B. Mitran¹, J. Garousi¹, M. Rosestedt¹, E. Lindström¹, K. G. Andersson², S. Ståhl², J. Löfblom², V. Tolmachev¹, A. Orlova^1;
1Uppsala University, Uppsala, SWEDEN, ²KTH-Royal Institute of Technology, Stockholm, SWEDEN.

68Ga-PSMA PET/CT for early restaging prostate cancer. Preliminary results of a prospective trial in patients with biochemical failure after radical therapy and PSA levels < 2 ng/mL
F. Ceci, P. Castellucci, T. Graziani, C. Fonti, F. Lodi, S. Boschi, S. Fanti; Service of Nuclear Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY.

SPECT/CT imaging of the PD-1/PD-L1 immune checkpoint pathway in syngeneic murine tumor models
S. Heskamp, J. D. M. Molkenboer-Kuenen, R. H. A. M. van de Vondervoort, O. C. Boerman; Radboud University Nijmegen Medical Centre, NIJMEGEN, NETHERLANDS.

Feasibility of in vivo imaging of VEGFR2 expression using high affinity antagonistic biparatopic affibody construct ZVEGFR2-Bp2
B. Mitran¹, R. Güler², E. Lindström¹, F. Fleetwood², V. Tolmachev¹, S. Ståhl², A. Orlova¹, J. Löfblom²;  ¹Uppsala University, Uppsala, SWEDEN, ²KTH Royal Institute of Technology, Stockholm, SWEDEN.

Prognostic significance of molecular and imaging biomarkers in primary brain tumors
E. Lopci¹, M. Riva¹, L. Olivari², F. Raneri², A. Bizzi³, B. Fernandes¹, P. Navarria¹, F. Pessina¹, M. Roncalli⁴, L. Bello¹, A. Chiti⁴;  ¹Humanitas Clinical and Research Hospital, Milano, ITALY, ²University of Milan, Milano, ITALY, ³Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, ITALY, ⁴Humanitas University, Milano, ITALY.

Value of F-DOPA PET in the long term follow up of radionecrotic brain metastases after radiosurgery: comparison with MRIF. Cicone¹, L. Carideo¹, C. Scaringi², A. Romano³, A. Bozzao³, G. Minniti², F. Scopinaro¹; ¹Unit of Nuclear Medicine, Sant’Andrea Hospital, “Sapienza” University of Rome, Rome, ITALY, ²Unit of Radiation Oncology, Sant’Andrea Hospital, “Sapienza” University of Rome, Rome, ITALY, ³Unit of Neuroradiology, Sant’Andrea Hospital, “Sapienza” University or Rome, Rome, ITALY.

A phage display derived stabilised bicyclic peptide targeting MMP-14 shows high imaging contrast in small animal PET imaging
A. M. Eder, S. Pavan, U. Bauder-Wüst, K. van Rietschoten, L. Baldassarre, U. Schierbaum, O. Seibert, K. Leotta, S. Campbell, H. Harrison, C. Stace, E. Walker, U. Haberkor, K. Kopka, D. P. Teufel; Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany

Tc-99m-CXCL8 SPECT to image disease activity in inflammatory bowel disease
E. Aarntzen, D. De Jong, R. Hermsen, J. Drenth, O. Boerman, W. Oyen; Radboud UMC, Nijmegen, Netherlands

Blunted striatal dopamine release in cannabis dependence
E. van de Giessen, J. Weinstein, C. Cassidy, M. Haney, M. Slifstein, A. Abi-Dargham; Columbia University College of Physicians and Surgeons/New York State Psychiatric Institute, New York, United States of America.

Synergistically Enhanced Tumor Uptake via Dual-Targeting of CD105 and EGFR Using a “Click” Heterodimer
R. Hernandez, H. Luo, H. Hong, S. A. Graves, R. J. Nickles, W. Cai; University of Wisconsin-Madison, Madison, United States of America.

Metastatic control probability in patients with prostate cancer metastatic to bone treated 186Re-HEDP
A. M. Denis-Bacelar, A. Divoli, S. Chittenden, Y. Du, G. D. Flux; Institute of Cancer Research, London, United Kingdom

Quantitative analyses at Baseline and Interim PET evaluation for response assessment and outcome definition in patients with Malignant Pleural Mesothelioma (MPM)
Egesta Lopci; Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), HUMANITAS (Rozzano), Milano, Italy

A comparison of EGFR-targeted and non-targeted 177Lu-labeled gold nanoparticles (AuNPs) for localized radiation treatment of breast cancer xenografts in athymic mice
Simmyung Yook; University of Toronto, Leslie Dan Faculty of Pharmacy, Pharmaceutical Sciences, Toronto, Canada

Validation and applications for SNAP-tag imaging of bacterial infection.
Bethany Mills; University of Nottingham, Nottingham, United Kingdom

Non-FDG-avid areas inside a tumour mass in Paediatric Hodgkin Lymphoma (PHL) patients – A new risk factor?
Lars Kurch; University Hospital of Leipzig, Department of Nuclear Medicine, Leipzig, Germany

The QUEST Study: Correlating metabolic response with 90Y PET dosimetry for the treatment of metastatic liver cancer with radioembolisation
Kathy P. Willowson; University of Sydney, Sydney, Australia

Development and pre-clinical evaluation of a new glucose-dependent insulinotropic polypeptide (GIP) based radioligand for PET imaging of a broad spectrum of neuroendocrine tumors
Eleni Gourni; University Hospital, Department of Nuclear Medicine, Freiburg, GERMANY

Synergistic anti-cancer response to chemotherapy and 177Lu-labelled APOMAB® radio immunotherapy in a preclinical model of lung cancer
Alexander Staudacher; Experimental Therapeutics Laboratory, Hanson Institute, Adelaide, AUSTRALIA

Tc99m labelled S-HYNIC Certolizumab Pegol for selecting patients for anti-TNFα treatment: a biodistribution and dosimetric study
Bieke Lambert; Department of Nuclear Medicine, Ghent University Hospital, BELGIUM

PET-guided radiotherapy planning in prostate cancer patients
Egesta Lopci; Humanitas Clinical and Research Center, Milan, ITALY

Evaluation of primary tumour and regional lymph node metastases with FDG PET/CT in breast cancer patients: prone versus supine position
Suzana Teixeira; Dutch Cancer Institute, Amsterdam, NETHERLANDS.